ascpannualmeeting1000false2011/2011-10-18T18:05:04.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARD2011/AM11FNV/2011-10-18T18:05:19.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARD2011/AM11FNV/101 Changes In the Fellowship Match Process.pdf2011-10-18T21:04:31.000Z"18d2a672f921b313f6dddf863006ff22"778970STANDARD2011/AM11FNV/104 White Blood Cell Identification A Novel Trainer and Competency Assessment Tool.pdf2011-10-18T21:05:18.000Z"238aaf77da44a991c4f3fe871b13aa28"1470290STANDARD2011/AM11FNV/106 Advancing the Global Workforce in Developing Countries Diagnostics to Logistics to Solutions.pdf2011-10-18T21:06:17.000Z"9321f913b7fcdc237546775b6b2d196a"662045STANDARD2011/AM11FNV/108 Improving Tissue Traceability by Internationally Standardized Coding.pdf2011-10-18T21:06:39.000Z"83c211eac72f74a8667d6f47364bad80"493283STANDARD2011/AM11FNV/11 Pathologists' Assistants and Their Role in the Practice of Pathology.pdf2011-10-18T20:01:37.000Z"62a47cdd6763cc9814d92c43e0d1722f"232743STANDARD2011/AM11FNV/111 Circulating Tumor Cells (CTCs) in Cytology.pdf2011-10-18T21:07:07.000Z"8526bcc09f7a76f785bf073f09a3ecc8"729926STANDARD2011/AM11FNV/113 Improve Lab Operations with Six Sigma Metrics.pdf2011-10-18T21:07:33.000Z"687a506d3cf9dd5e1af733059db7f972"2496370STANDARD2011/AM11FNV/114 The Anatomic Pathologist's Role in Error Reduction and Patient Safety.pdf2011-10-18T21:09:01.000Z"7b9eca801cae438b146cfea0f6bed794"2261656STANDARD2011/AM11FNV/115 Endothelial Progenitor Cells A Novel Laboratory-Based Biomarker of Vascular Health.pdf2011-10-18T21:10:16.000Z"c996c722b005403c604d9dbe24738b00"860155STANDARD2011/AM11FNV/116 The Future Role of Laboratory Inspections and Accreditation.pdf2011-10-18T21:11:01.000Z"f3158bb5db4fc9fc2ed3f914ae5ba7c5"873920STANDARD2011/AM11FNV/117 Applying Risk Management Principles to QA in Surgical Pathology From Principles to Practice.pdf2011-10-18T21:11:40.000Z"8975fe239f10b1a5d6ca0a47f804b59d"1310946STANDARD2011/AM11FNV/118 Managing Results in the New World of the Electronic Record.pdf2011-10-18T21:12:35.000Z"54ee0c67a926aa98007f3753328fc578"315401STANDARD2011/AM11FNV/119 Laboratory Medicine Best Practices Developing and Applying Systematic Evidence Review and Evaluation Methods for Quality Improvement.pdf2011-10-18T21:12:55.000Z"e859f8f2077073689b1fa9bd538ddd81"2027259STANDARD2011/AM11FNV/120 POCT in a Changing Regulatory World.pdf2011-10-18T21:14:04.000Z"a17fd61f9ca89027de6277fa0983c8a8"671761STANDARD2011/AM11FNV/124 Most Common Findings from Joint Commission Surveys.pdf2011-10-18T21:14:35.000Z"f0c5063994d3fa96a715b87399a4ed87"179463STANDARD2011/AM11FNV/126 Improving Your Decision Making Skills to Improve Laboratory Performance.pdf2011-10-18T21:14:45.000Z"6e3d5e1b22a8c12ae7b6871002a73053"300278STANDARD2011/AM11FNV/127 Lean in Action Using Lean Principles to Solve Impossible Problems.pdf2011-10-18T21:15:09.000Z"0a2d88a6d229ca27a6fc19da739a7cbf"260341STANDARD2011/AM11FNV/128 Strategic Planning How to Create and Implement a Plan to Achieve Your Vision for Your Laboratory.pdf2011-10-18T21:15:23.000Z"233234acd7d4701fcfe1545e5d424592"265596STANDARD2011/AM11FNV/129 Congratulations Residency Graduate What Every New Pathologist Should Know About Employment Decisions!.pdf2011-10-18T21:15:39.000Z"0fe3dc4a7053f306a6f3920596736613"185045STANDARD2011/AM11FNV/13 Fine Needle Aspiration Cytology of Metastatic Malignancies of Unknown Primary Site.pdf2011-10-18T20:01:53.000Z"ad48c8f7903e51cd9fd4cd0f3d9cecf2"19047748STANDARD2011/AM11FNV/131 Staff Motivation & Retention Possible Solutions to an Ongoing Challenge.pdf2011-10-18T21:15:49.000Z"747b9cb2119e07948805b5378e920246"297798STANDARD2011/AM11FNV/132 What Would You Do Case Studies in Laboratory Ethical Dilemmas.pdf2011-10-18T21:15:55.000Z"340e1fc84a3e1641a91604db6ff2dd49"359128STANDARD2011/AM11FNV/133 The Entrepreneur Within You Imagine!.pdf2011-10-18T21:16:16.000Z"1ec802d94fd00e46b3ad678fe5feb56b"125218STANDARD2011/AM11FNV/134 A Laboratory Cage Match Six Sigma vs. Lean.pdf2011-10-18T21:16:24.000Z"fadea8f42aa58dff20708d1a823da63f"186656STANDARD2011/AM11FNV/136 Risk Management and Legal Issues for the Practice.pdf2011-10-18T21:16:41.000Z"702187481525a706c14ddf822892175f"215818STANDARD2011/AM11FNV/138 Developing the Right Negotiation Skills for the Laboratory.pdf2011-10-18T21:16:58.000Z"090e135db66c27e41b7639afed6b21a8"171272STANDARD2011/AM11FNV/139 Making the Change from Lab Mentality to Customer Service Mentality (Part 1).pdf2011-10-18T21:17:10.000Z"381a99563425e5a8487fe97ddd07ac18"431455STANDARD2011/AM11FNV/14 Cytologic Sub-Classification of Lung Cancer A New Challenge for Practicing Pathologists.pdf2011-10-18T20:12:41.000Z"a2696ff3f15c4a768415800d28954750"812102STANDARD2011/AM11FNV/141 The Role of the Laboratory Director Responsibilities, Expectations and Challenges.pdf2011-10-18T21:17:28.000Z"e6e0fa4fe918753fa9e732739ce0ee34"180621STANDARD2011/AM11FNV/142 Making the Change from Lab Mentality to Customer Service Mentality (Part 2).pdf2011-10-18T21:17:37.000Z"d20725997e1fa0dff0ff6ae849c3c3d9"327614STANDARD2011/AM11FNV/143 Changes on the Horizon-An Update on Pathology Convergence.pdf2011-10-18T21:17:51.000Z"61b94921a0d843342d1df1238a3cb183"393587STANDARD2011/AM11FNV/144 Getting to Yes with Multigenerational, Multicultural Team Members.pdf2011-10-18T21:18:09.000Z"62adf443a8f7e7eb57ceb1134ef529c5"161130STANDARD2011/AM11FNV/147 Personalized Medicine-Current and Future Realities.pdf2011-10-18T21:18:15.000Z"4a7c331f97cd671c4a37fa0bd00bccef"134183STANDARD2011/AM11FNV/149 Gene Patents-The Future of Gene Research in an Era of Patents-Scientific and Legal Considerations.pdf2011-10-18T21:18:22.000Z"de5d961474cf8a16fdcd364ac7a39b1d"573549STANDARD2011/AM11FNV/152 Infections without Borders.pdf2011-10-18T21:18:41.000Z"16b49a00a36c3950747d177818acbfb5"798809STANDARD2011/AM11FNV/153 Tissue Tug of War Issues in Tissue Procurement for Research and Banking.pdf2011-10-18T21:19:13.000Z"67a5cb27a1cdaa382c5071ffa233e2a9"322776STANDARD2011/AM11FNV/155 Pathology Consultations-Making Them Effective and Relevant.pdf2011-10-18T21:19:32.000Z"cae412eaabee93a6c4b4c57f70975aa5"1155297STANDARD2011/AM11FNV/160 International Pathology and the World Health Organization.pdf2011-10-18T21:20:17.000Z"d0fb1a67ce58aa017e77e91719392bcd"492310STANDARD2011/AM11FNV/161 The Thyroid in Art.pdf2011-10-18T21:20:41.000Z"d3b6f4a499466f0ab615e75e9b904bed"19439287STANDARD2011/AM11FNV/169 Teach An Entire Pathology Course, Lecture and Lab, Online!.pdf2011-10-18T21:30:52.000Z"03b5a3063bb8f088afa5277f2599c121"395532STANDARD2011/AM11FNV/170 Peer Brainstorming Doping Yesterday, Today, Tomorrow Is the Clinical Laboratory Able to Detect the Use of Doping Substances in Non-official Competitions.pdf2011-10-18T21:31:14.000Z"a86c86e19fb6893288c55bac43ce0681"1011960STANDARD2011/AM11FNV/171 Crossing Borders Discovering Exotic Diseases That Have Become Endemic.pdf2011-10-18T21:31:40.000Z"b4b14a075f26a35afbcfee4c62ae17eb"1583529STANDARD2011/AM11FNV/173 ENCORE! Handling Patient Diagnostic Materials Ethical, Social, and Legal Issues.pdf2011-10-18T21:32:27.000Z"f803022d6fe553a0ca45dafad3dfb63d"148982STANDARD2011/AM11FNV/176 Liver Biopsy Evaluation A Novel Approach To Arriving at Differential Diagnosis.pdf2011-10-18T21:32:38.000Z"1d31c43ab96b6595cc85b29a3eaead98"1705056STANDARD2011/AM11FNV/177 2011 ASCP Resident Review Mini-Course Series Session 1 Microbiology, Chemistry and Transfusion Medicine.pdf2011-10-18T21:33:23.000Z"523586eaf88e75773659eed08ab2fb34"1022600STANDARD2011/AM11FNV/178 2011 ASCP Resident Review Mini-Course Series Session 2 Renal and Soft Tissue Pathology.pdf2011-10-18T21:34:05.000Z"e6180c5b9a238be64c6ffe8b564e73c4"8232992STANDARD2011/AM11FNV/184 Cutaneous Lymphomas Morphology, Immunohistochemistry and Molecular Testing.pdf2011-10-18T21:38:20.000Z"37e5b88bdae8ae4996f5da384b62626d"3650947STANDARD2011/AM11FNV/189 Evaluating and Reporting Tumors after (Neo)adjuvant Therapy Breast,Testis and Urinary Bladder.pdf2011-10-18T21:20:24.000Z"97e1b58c44a2c81e59f147ccd2daed58"5117266STANDARD2011/AM11FNV/191 Understanding Genitourinary System Cytology From Morphology to Molecular Pathology.pdf2011-10-18T21:23:36.000Z"87ffaa0dda9bb98ced81205b81ead319"253226STANDARD2011/AM11FNV/196 Develop and Maximize Your Team's True Potential.pdf2011-10-18T21:24:33.000Z"a3d2b98c7548db01d6d4daa0b71dbfea"1728896STANDARD2011/AM11FNV/2 Glands Gone Wild Glandular Lesions in Pap Tests.pdf2011-10-18T19:46:24.000Z"882ecdaa8409a9af6711f4b2519c6c74"12027539STANDARD2011/AM11FNV/2011 session list.docx2011-10-18T21:35:52.000Z"63f32dd29d37f6f19586c5d5dae4f3a4"24740STANDARD2011/AM11FNV/2011AM-accreditation.pdf2011-10-19T15:01:59.000Z"8cec81b18a50126433faa82e9f771972"49688STANDARD2011/AM11FNV/206 Myelodysplastic Syndromes (MDS), Aplastic Anemia, and Other Bone Marrow Failure States.pdf2011-10-18T21:25:39.000Z"e643ae51428725a1f9c3a3d418df3b25"3403868STANDARD2011/AM11FNV/214 Diagnosis of Infectious Diseases in Surgical and Cytopathology with Microbiology Recommendations.pdf2011-10-18T21:27:43.000Z"3eb52f01a85c6ba69a83ccb43f2a72a6"5824936STANDARD2011/AM11FNV/215 Problematic Cases in Pulmonary Cytopathology.pdf2011-10-18T21:30:28.000Z"09187ef941876c8b97253b1fab8e6a5f"1137778STANDARD2011/AM11FNV/217 Gynecologic Familial Cancer Syndromes What the Practicing Pathologist Needs to Know.pdf2011-10-18T21:31:11.000Z"6e2519b3f322c1e74e254929412cb752"694542STANDARD2011/AM11FNV/220 Urinary Cytopathology - Its Role in Diagnostic Uropathology and Relationship to Ancillary Tests like FISH.pdf2011-10-18T21:31:31.000Z"95b15f46f7960559b5694e872bcd754f"1873782STANDARD2011/AM11FNV/223 Applied Information Technology - Where Simplicity brings blissful surprises.pdf2011-10-18T21:32:29.000Z"1c9f3aa6b85c1ed20077c0f71b79057c"502247STANDARD2011/AM11FNV/224a Pulmonary Pathology New and Evolving Concepts, Diagnostic Dilemmas and Controversies (Part 1- Cases).pdf2011-10-18T21:32:47.000Z"648f6061e1be7fa273d155171f3dc1ff"155834STANDARD2011/AM11FNV/225 Global Standardization and Quality Services of Molecular-Genetic Testing.pdf2011-10-18T21:32:55.000Z"f7cf07f5957acf528cd4b497d3c0e6fb"4097481STANDARD2011/AM11FNV/230 Quality Assurance Programs and Revalidation Exploration and Opportunities for Collaboration at an International Level.pdf2011-10-18T21:34:56.000Z"edc3184c43573285ed933d688a64734b"138274STANDARD2011/AM11FNV/231 Barbara M. Castleberry Lecture for Laboratory Professionals.pdf2011-10-18T21:35:04.000Z"8592a644ed032745c65d37d6e6a49370"1580304STANDARD2011/AM11FNV/29 Common Consultation Conundrums in Breast Pathology.pdf2011-10-18T20:13:02.000Z"e218b1745ae6d7cf29f72655cb2a8526"8293660STANDARD2011/AM11FNV/3 Building Blocks of Cytodiagnosis The “Gut Course” in FNA Biopsy.pdf2011-10-18T19:47:08.000Z"f4cb2431b5c67bd5308ba65cbe4433b9"2875048STANDARD2011/AM11FNV/31 Surgical Pathology of Diagnostically Challenging Thyroid Gland Lesions.pdf2011-10-18T20:17:34.000Z"1ff571d5fe1eba75357e6df3525ce433"20344895STANDARD2011/AM11FNV/33 Special Types of Invasive Breast Carcinoma Diagnostic Criteria with Prognostic and Therapeutic Signs.pdf2011-10-18T20:30:40.000Z"7d2fa37db182ee50a39d50698b450faf"9920295STANDARD2011/AM11FNV/36 An Integrated Clinicopathologic Approach to Ever-Confusing Thyroid Pathology.pdf2011-10-18T20:38:42.000Z"090701741432f468c1308a47678f374e"7248197STANDARD2011/AM11FNV/37 Pitfalls in Dermatopathology When Things Are Not What They Seem To Be.pdf2011-10-18T20:43:31.000Z"1b65ed3fb31f65b617b1a8dc2d6f6a34"158358STANDARD2011/AM11FNV/39 Wart's Happening HPV disease of the cervix, vulva and anus with an update on laboratory testing and the vaccine.pdf2011-10-18T19:55:11.000Z"ea960aee00c201d66551e316f20a0043"5206047STANDARD2011/AM11FNV/4 Utilize CLMA’s “Body of Knowledge for Medical Laboratory Management” to Achieve ASCP’s DLM Certification.pdf2011-10-18T19:50:31.000Z"ab27e9be9cb3b02740156c1de96bd8b2"2800360STANDARD2011/AM11FNV/40 Surgical Pathology of Sinonasal Tract Tumors.pdf2011-10-18T19:58:22.000Z"171ccd0b6d726e2476c705dfdbe1e65b"14387253STANDARD2011/AM11FNV/41 A Crash Course in Diagnosing Common and Not-So-Common Head and Neck Lesions.pdf2011-10-18T20:06:48.000Z"bb0cadab0d1844e012dbbb89873ee39e"26037583STANDARD2011/AM11FNV/46 Medical Liver Biopsy Interpretation A Practical Guide for Accurate Diagnosis and Informative Reporting.pdf2011-10-18T20:22:54.000Z"acb59c7db24eb7ce736532b67b9afbbf"5166167STANDARD2011/AM11FNV/47 ENCORE! GI Pathology New Approaches to Old Problems.pdf2011-10-18T20:26:32.000Z"b78db6581155a9ddfc902af4529b8bfa"601609STANDARD2011/AM11FNV/48 Prostate Needle Biopsy Interpretation and Reporting Contemporary Issues and Emerging Concepts.pdf2011-10-18T20:27:09.000Z"ca8dc17b55356a3c6b6075ca4e1926cd"4124353STANDARD2011/AM11FNV/5 2011 AP Slide Seminar Tumors and Tumor-like Lesions of the Urinary Bladder.pdf2011-10-18T19:52:34.000Z"4a7c2419b8de38d9c1361d8e1022a9f9"544507STANDARD2011/AM11FNV/50 ENCORE! Pancreas Surgical Pathology and Cytopathology of Pancreatic Neoplasms.pdf2011-10-18T20:29:49.000Z"c5c6039ed4438598033ab8c0689bf7fb"3090883STANDARD2011/AM11FNV/51 Non-neoplastic Diseases of the Genitourinary Tract A Practical Approach and Diagnostic Pitfalls.pdf2011-10-18T20:32:00.000Z"294b28046da3807109d54d92492aed30"4229456STANDARD2011/AM11FNV/52 Top Ten Advances in Gastrointestinal Pathology 2011.pdf2011-10-18T20:35:21.000Z"3e8cf2511c8c07370888ffbca91b11e7"1167455STANDARD2011/AM11FNV/53 Clinico-Pathologic Dilemmas in Inflammatory Bowel Disease.pdf2011-10-18T20:36:17.000Z"73a380ce571bf2c59f9c11d35bf2bcb4"2295372STANDARD2011/AM11FNV/55 Important Pathologic Parameters in Reporting Urothelial Carcinoma of The Bladder.pdf2011-10-18T20:37:52.000Z"ad092fc5e280b56f81dc1d07b84e155b"306311STANDARD2011/AM11FNV/59 What You and the Neurosurgeon Really Need to Know Intra-operative Neuropathology.pdf2011-10-18T20:38:09.000Z"6d6a920fb73a69f41412cfc85dbeda0c"5753211STANDARD2011/AM11FNV/6 Challenging Cases for the Cytopathology Professional During Immediate Assessment. Are You Prepared.pdf2011-10-18T19:53:03.000Z"594e1b0f38b3809fc6d1eb337a6ab7c6"305636STANDARD2011/AM11FNV/60 Molecular Biology of Cartilage Neoplasis Current Concepts and New Advances.pdf2011-10-18T20:42:12.000Z"148934f09235c655987ef91af41ec841"1589097STANDARD2011/AM11FNV/61 Lost Mass Casualty Identification of Human Remains.pdf2011-10-18T20:43:21.000Z"0eabe61c0f7f1c74062ad89cd81fb551"2212413STANDARD2011/AM11FNV/64 Implementing Blood Management.pdf2011-10-18T20:44:59.000Z"9f51b5ae85bd0c6e0adf50f6d30ab1d3"1000668STANDARD2011/AM11FNV/65 Evidence-based Uses and Abuses of Plasma Transfusion.pdf2011-10-18T20:45:36.000Z"539c5725748805048256308e1f7f17b2"790666STANDARD2011/AM11FNV/66 Contemporary Issues in Diagnostic Hemostasis and Thrombosis.pdf2011-10-18T20:46:19.000Z"7bb0a061ac5ef2d31f5f3c3a85ad9ec3"2964857STANDARD2011/AM11FNV/67 Pharmacodynamic Monitoring of Targeted Drug Therapy.pdf2011-10-18T20:54:18.000Z"7f72e7242e07d50b5a005e0905f8de73"7543895STANDARD2011/AM11FNV/70 Diagnostic Accuracy.pdf2011-10-18T21:00:32.000Z"f9320c483ba6143c0e5e319733a3b905"336510STANDARD2011/AM11FNV/72 Procalcitonin as a Marker of Infection, Sepsis, and Response to Antibiotic Therapy.pdf2011-10-18T21:00:53.000Z"bff033240904734190f93aab7f8d27d4"919042STANDARD2011/AM11FNV/73 Coagulation Laboratory Methods, Standards and Cost Effective Testing (Part 1).pdf2011-10-18T20:43:39.000Z"cb0bdddfc0485c7d2c30251ff0bbf9a6"176145STANDARD2011/AM11FNV/74 Coagulation Laboratory Methods, Standards and Cost Effective Testing (Part 2).pdf2011-10-18T20:43:54.000Z"8e6ef0281353c774f09407c12f32639d"228501STANDARD2011/AM11FNV/75 Half the Sky in Hematopathology Diagnosis of Lymphoma With Limited Resources.pdf2011-10-18T20:44:09.000Z"5fbfc5b98eef906c3b78500a4e19164b"3022440STANDARD2011/AM11FNV/76 Molecular GeneticsImmunophenotype in New Entities of the 2008 WHO Classification of Hematopoietic Neoplasms.pdf2011-10-18T20:45:44.000Z"15550271b2c22d75672ad6bc0643eea0"308357STANDARD2011/AM11FNV/77 Flow Cytometry Basic Analysis Principles of Hematopoietic Malignancies.pdf2011-10-18T20:45:56.000Z"a21f880dacb1f8e00191fa7cab00868b"2100605STANDARD2011/AM11FNV/78 The Power of Peripheral Blood Smears-Apparent Diagnostic Clues (Part 1).pdf2011-10-18T20:47:50.000Z"d118e5037467f039ef5f6ae1c8d6336e"332919STANDARD2011/AM11FNV/79 Hemoglobinopathies The How, Why and What.pdf2011-10-18T20:48:09.000Z"0b662a061b1f61183ef9a60d1d7a4089"279703STANDARD2011/AM11FNV/8 Classifying Your Thyroid FNA Specimens Using Bethesda Terminology Use of Adjunct Molecular Reflex Testing.pdf2011-10-18T19:53:25.000Z"73044d5124757c43d54771a3542c36f5"947300STANDARD2011/AM11FNV/80 Myeloproliferative Neoplasms New Approaches to Diagnosis and Disease Monitoring.pdf2011-10-18T20:50:33.000Z"bd49cce06ca96af05fcc18fc1ecc931b"2799212STANDARD2011/AM11FNV/81 Stump the Stars 2011 Problem Cases in Hematopathology_pre meeting.pdf2011-10-18T20:54:33.000Z"be1406a1ab3d3b39bd4b1b8fa8e253e1"8786503STANDARD2011/AM11FNV/81 kroft_hsi_reichard_brynes_peterson POST MEETING.pdf2011-10-18T20:52:33.000Z"d6c54c55e3452a928ed8f3805778b41b"2950042STANDARD2011/AM11FNV/83 The Power of Peripheral Blood Smears-Apparent Diagnostic Clues (Part 2).pdf2011-10-18T21:01:55.000Z"940ea08637660cd7b5c274d949e19acf"414540STANDARD2011/AM11FNV/84 Immunohistochemistry to the Rescue in Hematopathology Problem Cases.pdf2011-10-18T21:02:18.000Z"276b9ea9ccc1d3ed723c5ca9228330b7"12293787STANDARD2011/AM11FNV/86 FDA Regulation of Laboratory-Developed Tests.pdf2011-10-18T21:10:26.000Z"1f8425b937b61de44ff9ed018cd2823a"475616STANDARD2011/AM11FNV/87 Recent Advances in HPV Testing.pdf2011-10-18T21:10:50.000Z"310a1b6562488095c2a2c45098d37f66"1232486STANDARD2011/AM11FNV/89 Emerging Molecular Diagnostic Tests and Therapies for Melanoma.pdf2011-10-18T21:11:40.000Z"18d79e37d03508ef410f88147712963c"879434STANDARD2011/AM11FNV/9 Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-Cell Lymphomas.pdf2011-10-18T19:53:55.000Z"df88749852a4408332e3b9a30bfb9637"175051STANDARD2011/AM11FNV/90 A Practical Approach to Molecular Diagnostics in Gynecologic Neoplasms.pdf2011-10-18T21:12:52.000Z"04b92a99aa960b45317ea77edeab63f1"2693868STANDARD2011/AM11FNV/92 Molecular Pathology in a Community Hospital Setting.pdf2011-10-18T21:16:19.000Z"525504d2facc5de1d26e8b3fc80635ce"4917699STANDARD2011/AM11FNV/94 Defining Best Practices for Determining KRAS Mutations in Colon Cancer.pdf2011-10-18T21:19:22.000Z"e12cc29568f3115980750d36864dd1b0"1583627STANDARD2011/AM11FNV/95 Maintenance of Certification Primer.pdf2011-10-18T21:19:59.000Z"d407595a7c73129967dfa5887f80171f"176303STANDARD2011/AM11FNV/96 What You Need to Know for the APCP Boards.pdf2011-10-18T21:20:09.000Z"dbf36d22a6525d61fb68c30c7be42d38"156911STANDARD2011/AM11FNV/99 Don't Be Mystified, Be Certified! Opportunities on a Global Scale.pdf2011-10-18T21:03:59.000Z"c8e67d446ff713df4636562ece0ebdeb"369752STANDARD2011/AM11FNV/9a From Morphology to Molecular Pathology A Practical Approach for Cytopathologists (Part 1 Cytomorphology).pdf2011-10-18T19:54:33.000Z"f5d06145f62ecffa8534e8b91418f210"7506397STANDARD2011/AM11FNV/9b From Morphology to Molecul...Part 2 Molecular Testing).pdf2011-10-18T19:58:40.000Z"66c35271406ca5d2f757ff4242da905d"4215883STANDARD2011/AM11FNV/CSP02 Uncommon Gastrointestinal Disorders Ignorance is Not Bliss.pdf2011-10-18T21:35:58.000Z"22eee4884d7a91947277082cbeb680ea"3695815STANDARD2011/AM11FNV/CSP04 Topics in Hematopathology Flow Cytometry and Molecular Genetics as Tools for Understanding, Diagnosing, and Treating Hematolymphoid Malignancy.pdf2011-10-18T21:39:57.000Z"26acdad66bc7db9c911d8f9707585feb"8560990STANDARD2011/AM11FNV/CSP06 Head and Neck Pathology Challenges and Opportunities.pdf2011-10-18T21:47:05.000Z"f9f52daad6c86e1aa6828d2cd6aa113a"13763273STANDARD2011/AM11FNV/Program.pdf2011-10-19T15:02:05.000Z"11b7f36ff9abdd7668becbc7e15aed2b"140188STANDARD2011/AM11FNV/SAM.pdf2011-10-19T15:02:21.000Z"bde65cd7e98071f2483104003ff18972"77626STANDARD2011/AM11SA/2011-11-03T16:03:56.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARD2011/AM11SA/1.pdf2011-11-03T16:21:35.000Z"ef52b04ea7eecdc7feaafa0dfb3386a0"10949005STANDARD2011/AM11SA/10.pdf2011-11-03T18:09:57.000Z"06110339803cf0672107db6c29c4b0e4"5781415STANDARD2011/AM11SA/101.pdf2011-11-04T03:59:29.000Z"ea95fd06a8eb8cfd12272f4b3bb8170c"1054759STANDARD2011/AM11SA/104.pdf2011-11-07T21:09:33.000Z"3dc42160f4f2561d0f5624ca0254461a"4060233STANDARD2011/AM11SA/105.pdf2011-11-03T22:58:56.000Z"0b3c9337153237a61e48a27ddd329e99"254271STANDARD2011/AM11SA/106.pdf2011-11-03T23:01:01.000Z"7034fdb73b89893e27bb5a189d02359a"1807914STANDARD2011/AM11SA/107.pdf2011-11-16T22:00:06.000Z"4caad904cb4fc48429d21e4f02e5abbb"26723204STANDARD2011/AM11SA/108.pdf2011-11-16T22:31:35.000Z"6700d8c9dbe6fbff4225c222ded4bf76"26946313STANDARD2011/AM11SA/109.pdf2011-11-16T22:48:57.000Z"1675ca3028df0c9e1c749b4c05537781"13928084STANDARD2011/AM11SA/11.pdf2011-11-03T18:14:49.000Z"ddfee342ceb465d9feacdd659da9e77b"1479251STANDARD2011/AM11SA/111.pdf2011-11-03T23:36:48.000Z"666048512105661e6da5d42e6386c32c"3850986STANDARD2011/AM11SA/114.pdf2011-11-16T22:59:39.000Z"bbb8a79ff18e36d6343ac9b6ca0e0b12"9168848STANDARD2011/AM11SA/115.pdf2011-11-03T23:55:24.000Z"6ff91a3890f71e4add9f0dfd52ac06fe"1458151STANDARD2011/AM11SA/116.pdf2011-11-06T20:44:39.000Z"ccb507a135efbce87121807136031dc8"3644389STANDARD2011/AM11SA/117.pdf2011-11-04T13:17:50.000Z"ab0f5eddce3b0ddf6734326b4a2310fa"3665763STANDARD2011/AM11SA/118.pdf2011-11-04T00:13:28.000Z"d9c070be9eb6035c88ef28f4489f2b3d"432644STANDARD2011/AM11SA/119.pdf2011-11-09T13:27:08.000Z"8f1981b9a7eaf712183af1129c52021d"4104227STANDARD2011/AM11SA/12.pdf2011-11-03T18:16:58.000Z"92439d33e33700eba329a18cceac3b4a"3455633STANDARD2011/AM11SA/120.pdf2011-11-06T21:09:14.000Z"09b3838b3efe52a76c3cf107e79555fe"2519707STANDARD2011/AM11SA/124.pdf2011-11-04T00:32:37.000Z"c6e8dc1a52c56b39a66f61a73c2b8beb"317691STANDARD2011/AM11SA/126.pdf2011-11-04T00:32:48.000Z"8bc88acdbd2d502a6119a0829304b97d"500819STANDARD2011/AM11SA/127.pdf2011-11-04T00:33:06.000Z"c4a0edef6026e4ff9a45b881e10fc4f6"713338STANDARD2011/AM11SA/128.pdf2011-11-04T00:36:04.000Z"f9915eacf91943447d1bb9bb6baf7bc4"2166863STANDARD2011/AM11SA/129.pdf2011-11-04T00:38:01.000Z"86222ffeddc3df18e732e84e333407a7"374920STANDARD2011/AM11SA/13.pdf2011-11-03T18:20:24.000Z"f9c27963d78ddd899445852121e6a240"5238215STANDARD2011/AM11SA/130.pdf2011-11-07T02:22:57.000Z"473248ec662757e31557d927289d60eb"4203107STANDARD2011/AM11SA/131.pdf2011-11-16T23:04:15.000Z"db22bba102eb7761d9e8f282598f8c4c"19882507STANDARD2011/AM11SA/132.pdf2011-11-04T00:58:12.000Z"ffa8bca8290e0cbc3055f88029c866b2"825113STANDARD2011/AM11SA/134.pdf2011-11-04T00:58:47.000Z"67d4c898cc0a81ff7776e677be1b1e7c"214242STANDARD2011/AM11SA/135.pdf2011-11-04T01:02:42.000Z"4666e19bdec49d21bea008c35b9f663f"1698263STANDARD2011/AM11SA/137.pdf2011-11-16T23:20:30.000Z"0de02a846e53e263e64637010918cd94"16456675STANDARD2011/AM11SA/138.pdf2011-11-04T01:13:22.000Z"fbdca0e7f7a480a56bfb69fe44d919a3"1172052STANDARD2011/AM11SA/139.pdf2011-11-04T01:18:56.000Z"3a8e0cbe8de463fe2e97df618390b2a4"1226334STANDARD2011/AM11SA/140.pdf2011-11-04T01:19:56.000Z"90d1bf3e296dc849a77d323bdfa0a52a"656415STANDARD2011/AM11SA/141.pdf2011-11-04T01:20:47.000Z"2268f4683bf94083057a5ef21eec5bad"93269STANDARD2011/AM11SA/142.pdf2011-11-04T22:34:16.000Z"d30e0b652d64f7a3816e84b745b4eea2"1170117STANDARD2011/AM11SA/143.pdf2011-11-04T01:30:54.000Z"c2cabd7bf16319fa4cbf2d3c58a8e929"1389391STANDARD2011/AM11SA/144.pdf2011-11-04T01:31:51.000Z"2791d9b7ea0e8e6e49ccb13989cbf6de"1192679STANDARD2011/AM11SA/147.pdf2011-11-04T01:33:37.000Z"9542d50ba5f0bdf6d142c57d80174ee8"899106STANDARD2011/AM11SA/149.pdf2011-11-04T01:34:17.000Z"f64056fdefa2871363bd83e07c737f36"387071STANDARD2011/AM11SA/15.pdf2011-11-03T18:25:11.000Z"0bed41910fccc3b264d3d2bea59a4e67"14279402STANDARD2011/AM11SA/152.pdf2011-11-16T23:29:19.000Z"9f8d07de6542dd9e43decc1bbefa2c56"4088159STANDARD2011/AM11SA/153.pdf2011-11-04T01:48:41.000Z"0f2804c9ce4709d87a484359400edf31"2258058STANDARD2011/AM11SA/155.pdf2011-11-16T23:31:01.000Z"7e309b9356ffa682ad03358c5f78480d"8445196STANDARD2011/AM11SA/156.pdf2011-11-04T14:34:46.000Z"28eef8dbf75d95953cff125ed3e96093"1452980STANDARD2011/AM11SA/157.pdf2011-11-04T02:10:25.000Z"4017134d1132f34249d6c75add1e1080"2559920STANDARD2011/AM11SA/160.pdf2011-11-16T23:34:52.000Z"59467e964c5144fdc943bae0d2dbb8e4"12234422STANDARD2011/AM11SA/161.pdf2011-11-16T23:17:14.000Z"12e8a90655000531238216696912e795"20839392STANDARD2011/AM11SA/169.pdf2011-11-04T15:00:45.000Z"a01d44d16dbceb3f7ec1e42728b0f056"1220981STANDARD2011/AM11SA/170.pdf2011-11-16T23:27:32.000Z"3b348bcd8809ad708992d14d882cce13"8197534STANDARD2011/AM11SA/171.pdf2011-11-07T14:59:29.000Z"65f2c6170fe164c9a5e85cb979516d42"5208825STANDARD2011/AM11SA/172.pdf2011-11-16T23:31:30.000Z"704e50a29246de44f07a9a1a76c75cc8"7458145STANDARD2011/AM11SA/173.pdf2011-11-04T03:12:34.000Z"2dc5347a5a437cff45f9e6145a25caeb"316279STANDARD2011/AM11SA/175.pdf2011-11-16T23:35:21.000Z"5e308104eec9ad38d78783343ec3a32a"59370394STANDARD2011/AM11SA/177.pdf2011-11-17T00:05:45.000Z"353211c1f2071817c6f7c23292f28b3d"4225390STANDARD2011/AM11SA/178.pdf2011-11-16T23:40:45.000Z"500e7d93135aebfa37a9447c89439dd7"18336021STANDARD2011/AM11SA/179.pdf2011-11-16T23:49:13.000Z"9b23c8276668170986ca4de18cdc3122"14473670STANDARD2011/AM11SA/184.pdf2011-11-16T23:56:08.000Z"464c21fdb9840f37b243b604a6ed20d8"25405292STANDARD2011/AM11SA/189.pdf2011-11-17T00:16:33.000Z"6bc3ae27c63cdad28f5b7df2676a53dd"18936858STANDARD2011/AM11SA/191.pdf2011-11-17T00:26:06.000Z"d227513c0a5bf81e04f81e313db848f0"16467314STANDARD2011/AM11SA/2.pdf2011-11-03T16:36:54.000Z"0274dc9d80153f61ed22d5442ff13bdf"12720326STANDARD2011/AM11SA/204.pdf2011-11-17T00:08:02.000Z"0c5a4c6517258f81464727ed7f0edf01"10611832STANDARD2011/AM11SA/206.pdf2011-11-17T00:16:23.000Z"0cc3166612b0c874d1f99b627adde2f8"13099562STANDARD2011/AM11SA/214.pdf2011-11-17T01:16:34.000Z"1f25dcd8c0466ae974b78ba1cd945f29"65016131STANDARD2011/AM11SA/215.pdf2011-11-17T02:04:02.000Z"73fdf676daa64b3e1936961376839939"20622949STANDARD2011/AM11SA/220.pdf2011-11-17T02:12:49.000Z"7655c2e44959bbcf9d52f99d2334e444"8647200STANDARD2011/AM11SA/223.pdf2011-11-04T13:09:28.000Z"9aed4ffd6463c979de4eff7dcf768f13"2591576STANDARD2011/AM11SA/224a.pdf2011-11-17T01:21:55.000Z"b704b46de9e07afb9e352803795fcadc"45610305STANDARD2011/AM11SA/225.pdf2011-11-09T13:55:57.000Z"31329b1940e4ea55c554daf51ef40c58"5063028STANDARD2011/AM11SA/230.pdf2011-11-17T01:38:26.000Z"26f6de1cb651377032da98a4e078531f"21645858STANDARD2011/AM11SA/231.pdf2011-11-17T01:46:54.000Z"d7ae41363ea3701ef9d6aa18b6b3d42e"13563390STANDARD2011/AM11SA/29.pdf2011-11-03T18:36:40.000Z"297c1cccebee2b062f8719715354d474"3399397STANDARD2011/AM11SA/3.pdf2011-11-03T21:37:40.000Z"092be1370098a36e253ade38d706dfd4"27540582STANDARD2011/AM11SA/33.pdf2011-11-03T18:38:35.000Z"e110b7fa8feb051caf2730497efd1f82"31155701STANDARD2011/AM11SA/34.pdf2011-11-03T23:12:01.000Z"6dcd4faa8a4da9b7eb417e4b4b9ba0b5"23527448STANDARD2011/AM11SA/36.pdf2011-11-03T19:11:04.000Z"55153e374e4c031e86ac97f0d3dfa03b"12773960STANDARD2011/AM11SA/37.pdf2011-11-03T19:04:23.000Z"2e3eec5243cd4f5819ece4b5c5dc8799"22323882STANDARD2011/AM11SA/38.pdf2011-11-03T19:19:13.000Z"64d2a00c8040baa1359f1ebd04c0218b"22740884STANDARD2011/AM11SA/4.pdf2011-11-03T18:04:12.000Z"b4f3d15eb8572e184953f7c56e0ac1bc"322575STANDARD2011/AM11SA/41.pdf2011-11-03T23:22:49.000Z"7051d617ac1bb4f62a20337969f59d3f"19419003STANDARD2011/AM11SA/42.pdf2011-11-03T20:21:41.000Z"4397b42cd88811e92e3aa911fd2e8d4b"25698694STANDARD2011/AM11SA/46.pdf2011-11-03T21:04:23.000Z"5399f5e4cc048256696a01fdea66dd46"21957068STANDARD2011/AM11SA/47.pdf2011-11-03T19:39:04.000Z"59b511540320c87a5a5a02e90fd8ef2b"17871911STANDARD2011/AM11SA/48.pdf2011-11-03T19:53:05.000Z"054769e25c084d7a58e303469ebbc05c"11093686STANDARD2011/AM11SA/5.pdf2011-11-04T18:30:27.000Z"b1ed9f48042b748ebb7868462041f65b-2"82499928STANDARD2011/AM11SA/50.pdf2011-11-03T23:29:52.000Z"077c1e4a85f371f3749ba7691155a16c-2"70802664STANDARD2011/AM11SA/51.pdf2011-11-03T21:04:24.000Z"e7688086f20c1ea52b777ffa3bca21c5"13451548STANDARD2011/AM11SA/52.pdf2011-11-03T21:14:01.000Z"762df5068a83429a3bd5755830d7d87a"3104942STANDARD2011/AM11SA/53.pdf2011-11-03T21:17:02.000Z"0bdc65117251bd2a9dafd33ae1d378fe"5801148STANDARD2011/AM11SA/55.pdf2011-11-03T21:22:11.000Z"23c26558016594e24d6b88eb9b48e3bf"53200477STANDARD2011/AM11SA/59.pdf2011-11-03T22:05:05.000Z"c4f0628cb2cf9638ccf13993e715f5dd"19480829STANDARD2011/AM11SA/6.pdf2011-11-03T17:04:22.000Z"4725c4c8c8602873e0bfe1acd10dc205"36244713STANDARD2011/AM11SA/60.pdf2011-11-03T22:14:20.000Z"356b5f31be6ca920f703b880bf8b6948"16165681STANDARD2011/AM11SA/61.pdf2011-11-03T22:20:33.000Z"458360f9f6a40ed97657006c959708bb"21569248STANDARD2011/AM11SA/64.pdf2011-11-03T21:26:19.000Z"54171591001ffa5bcb3487373cd295a3"9993953STANDARD2011/AM11SA/65.pdf2011-11-03T21:33:16.000Z"79f5c1189da570eef4f5893301f65f98"793061STANDARD2011/AM11SA/67.pdf2011-11-03T21:33:39.000Z"e009a6fa887e0f69db3a374788d758e0"3587360STANDARD2011/AM11SA/68.pdf2011-11-03T21:35:21.000Z"6e8cb8f496bc4579c29f9a01ed921df7"1194018STANDARD2011/AM11SA/69.pdf2011-11-03T21:36:07.000Z"feb05e5a150cf9ea69e7dedc6b78fc0b"3038660STANDARD2011/AM11SA/7.pdf2011-11-03T17:40:26.000Z"add8d62fbdcc32caf6faa6e0002f69b6"1624800STANDARD2011/AM11SA/70.pdf2011-11-03T21:36:19.000Z"a7620e63ba7f7374d8dda0041e94a51c"1864757STANDARD2011/AM11SA/72.pdf2011-11-03T21:37:56.000Z"479a9191017bd6896f99a2ff06e60e6b"2536135STANDARD2011/AM11SA/73.pdf2011-11-04T03:15:37.000Z"0c40f2aa305474b67401548f8432a5af"1766291STANDARD2011/AM11SA/74.pdf2011-11-03T21:48:22.000Z"900658526d6a720b02300e0361ff2af5"2013658STANDARD2011/AM11SA/75.pdf2011-11-16T22:00:07.000Z"5ff1a8e92d7b0ba47ed1461ca2e1508f"25398644STANDARD2011/AM11SA/76.pdf2011-11-07T16:02:17.000Z"10aaf7954a12b5d71c78fb1ae4c370db"9640622STANDARD2011/AM11SA/77.pdf2011-11-16T22:16:53.000Z"e9fa49d40b2a78b6b64437a840370e0d"47135382STANDARD2011/AM11SA/78.pdf2011-11-04T15:38:33.000Z"e9b090ac0e11f583178558874c367b64"3511979STANDARD2011/AM11SA/79.pdf2011-11-16T22:42:45.000Z"ebff85a36da91917fb34c01c38c357b3"12934607STANDARD2011/AM11SA/8.pdf2011-11-03T17:43:24.000Z"2d70a1030b4ffdc1e6a19eb0b2d150e2"6317537STANDARD2011/AM11SA/80.pdf2011-11-16T22:51:06.000Z"ac1dd235a418f01e3e51ca411d7b8bff"4014632STANDARD2011/AM11SA/81.pdf2011-11-07T15:26:00.000Z"74fc4566e13a742c2d6f8c96c136de6a"14072704STANDARD2011/AM11SA/83.pdf2011-11-04T11:11:53.000Z"0176090dfe25f4e48f61156283b6d9a6"3438195STANDARD2011/AM11SA/84.pdf2011-11-07T15:53:08.000Z"d2e0e116dbe23643b669ba920d5ed173"22639918STANDARD2011/AM11SA/86.pdf2011-11-03T22:53:15.000Z"0386b1c93198a6498866ca62150db277"1424780STANDARD2011/AM11SA/87.pdf2011-11-07T16:08:33.000Z"7f1ce00115baaf0f814f6fb1d965bc1b"5089764STANDARD2011/AM11SA/88.pdf2011-11-07T16:15:32.000Z"8e2d169c186104764f6542d2d6f9d190"9927099STANDARD2011/AM11SA/89.pdf2011-11-04T04:55:22.000Z"8f3a844d7eec333ad3a207dac6d2f601"4051379STANDARD2011/AM11SA/9.pdf2011-11-03T17:50:08.000Z"9e54373f7e515e5daabc8413a8cfbfe3"4867113STANDARD2011/AM11SA/90.pdf2011-11-16T22:53:26.000Z"1239dc860a4e288cf576ee72b4a0f1c3"30946100STANDARD2011/AM11SA/92.pdf2011-11-04T05:24:17.000Z"a644358e070dd9085aea8ba13bfeedf0"2951942STANDARD2011/AM11SA/93.pdf2011-11-07T05:29:10.000Z"b54f06b30e789ec984b8366377f1343c"5765193STANDARD2011/AM11SA/94.pdf2011-11-16T21:28:09.000Z"3ef7292c34abf3dd87eb742a67fe1168"10559000STANDARD2011/AM11SA/95.pdf2011-11-04T00:01:08.000Z"9b1238539697f6491378e81ced0fe092"913677STANDARD2011/AM11SA/96.pdf2011-11-04T00:03:43.000Z"12824fb18dff7ec2a12f8bf5a39d1493"736250STANDARD2011/AM11SA/99.pdf2011-11-04T00:04:12.000Z"bb594339a036466c71c87a7382d9c96d"551519STANDARD2011/AM11SA/9a.pdf2011-11-03T17:54:20.000Z"bc76980f56886f34b9ce5adf8179f45b"5850941STANDARD2011/AM11SA/9b.pdf2011-11-03T18:04:13.000Z"6189a66517b5fa3d9e8158debe638947"7099868STANDARD2011/AM11SA/CSP02.pdf2011-11-17T15:16:42.000Z"663013f339efacb1505473b91725a57c"61084879STANDARD2011/AM11SA/CSP03.pdf2011-11-07T15:24:03.000Z"b6f888c7b5ec84b3552699f46f95fc04"6129048STANDARD2011/AM11SA/CSP05.pdf2011-11-17T14:51:33.000Z"4943d42bcb76da721defdd37593f3c62"7406860STANDARD2011/AM11SA/CSP06.pdf2011-11-17T14:51:37.000Z"3e27370ff9876eb457ee8b7f8bc92e5a"17849893STANDARD2011/AM11SA/MTE01.pdf2011-11-17T14:51:41.000Z"92d785882ef133a11fdf592cefeea15b"7974158STANDARD2011/AM11SA/MTE02.pdf2011-11-17T14:51:47.000Z"dbded2eb8d1119d915e2a49b58ef60d8"12017815STANDARD2011/AM11SA/MTE03.pdf2011-11-17T14:51:51.000Z"f8ee7e9efe1653517e6355b4f9a1e44e"11727405STANDARD2011/AM11SA/carolyn_pdf.docx2011-11-04T01:49:08.000Z"2a0c76072957a10d888d4ce5bf236faa"27768STANDARD2011/AM11VR/2011-10-18T18:05:30.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARD